Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar

Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against JEV, a cross-section...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngwe Tun, Mya Myat, Kyaw, Aung Kyaw, Nwe, Khine Mya, Inoue, Shingo, Thant, Kyaw Zin, Morita, Kouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227667/
https://www.ncbi.nlm.nih.gov/pubmed/34072933
http://dx.doi.org/10.3390/vaccines9060568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227667/
https://www.ncbi.nlm.nih.gov/pubmed/34072933
http://dx.doi.org/10.3390/vaccines9060568

Ejemplares similares